New UK Biosimilars Pathway Suffers Setback

MHRA Consultation Review Delayed Due To ‘Intense COVID-19 Activities’

 
• By David Wallace
Alarm Clock COVID coronavirus
The MHRA’s COVID-19 activities have delayed the new pathway • Source: Shutterstock

More from Biosimilars

More from Products